3rd International AIDS Society Conference on HIV Pathogenesis and Treatment Rio de Janeiro - July 24 - 27, 2005

PREVALENCE OF HIV, HEPATITIS B AND C VIRUSES IN HIGH RISK POPULATION IN ST. PETERSBURG, RUSSIA

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. TuPe1.1C12

Lioznov D., Nikolaenko S., Sabadash N., Antonova T., Belayeva T.
Pavlov State Medical University, St. Petersburg, Russian Federation

INTRODUCTION: Blood-borne infections remain a major public health challenge in Russia, exacerbated by the advent of the HIV epidemic. The goals of the study are to determine the seroprevalence of HIV, HCV and/or HBV among in-patients of a unit designed for homeless and/or marginalized adolescents and young adults and to characterize the HCV genotypes in seropositive individuals.

METHODS: Data were collected from 312 subjects referred to the Out-patient Unit of Center for Chronic Viral Infections Research, Pavlov State Medical University, St. Petersburg, Russia by NGOs and clinics for evaluation of the presence of blood-borne infection and clinical care in 2004. Serum samples were tested for antibodies against HIV (1/2), hepatitis C (HCV), and for hepatitis B surface antigen (HBsAg). The HCV-ab positive samples were tested for the HCV genotypes by RT-PCR.

RESULTS: The mean age of subjects was 23.9±5.2 years, 63.1% male. Forty-five subjects (14.4%) had no serological markers of HIV, HCV, or HBV. HBV or HCV mono-infection was found in 4.8% and 43.6% respectively. Thirty seven per cent of subjects were coinfected with HIV, HCV and/or HBV. Among all subjects antibodies to HIV-1 were found in 27.2%, 26.9% tested positive for HBsAg, while 80.8% were positive for HCV antibodies. Among 252 HCV-infected individuals HCV RNA were detected in 77.8% cases. The most prevalent genotype was HCV-3a (49.8%). HCV-1 was found in 34% and type 2a in 5% of patients. A mixed infection of type 1 with 2 or 3 was detected in 11 patients (5.6%). In 11 patients (5.6%) genotypes were undetermined.

CONCLUSIONS: These data indicate that hepatitis C is the most frequent pathogen in this high-risk population. High prevalence of coinfection among subjects and there social status impede access to lifesaving treatment and/or limit its effectiveness. There is need in effective prevention and care programs for this population.

Download PDF of this abstract.

050724
Clinical | TuPe1.1C12 | Dmitry Lioznov
Hepatitis viruses

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.